Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
To determine the efficacy (superiority) of Irbesartan compared to Placebo would reduce the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and death in patients with Atrial Fibrillation (AF) and with at least one major risk of vascular events.
Randomized, double-blind, efficacy study, placebo controlled, factorial design superiority trial.
Composite outcome of stroke, myocardial infarction, vascular death or hospitalization for heart failure
Heather Beresh, Laura Bonilla